Suzhou Alphamab To Start China Trial Of Biologic Infertility Treatment

Suzhou Alphamab will start a China Phase I trial for KN015, a biologic treatment for infertility. It is the first of Alphamab's novel biologic/biosimilar programs to reach the clinic. KN015 is a long-acting human follicle-stimulating hormone (FSH), used as part of an assisted reproductive therapy to develop multiple follicles in women. Unlike other currently available programs, KN015 is expected to require only a single injection, rather than daily injections, because of its enhanced half-life.